Wave Life Sciences: stock performance and business snapshot

Wave Life Sciences (WVE) has been drawing attention after recent trading, with the stock closing at $6.38 and posting mixed returns over different periods, including a decline of about 14% over the past month.

Recent trading has been weak, with the share price down 52.71% over the past 90 days and 60% year to date. Meanwhile, longer term total shareholder returns of 7.23% over one year and 74.32% over three years point to a mixed but still constructive overall picture.

If you are comparing Wave Life Sciences with other high potential healthcare names, it may be worth scanning for RNA, genomics, and related biotech opportunities through a dedicated healthcare AI stock screener such as 34 healthcare AI stocks.

With revenue of US$71.8 million, a reported net loss of US$183.6 million and a recent close at US$6.38, the key question is whether current weakness leaves upside on the table or whether the market already prices in future growth.

Most Popular Narrative: 71.2% Undervalued

Against a last close of $6.38, the most followed narrative pegs Wave Life Sciences' fair value at $22.19, framing a wide gap that hinges on future execution.

The upcoming clinical data readouts for key programs (AATD with WVE-006 and obesity with WVE-007) in late 2025 and early 2026 represent potential inflection points, supported by strong early efficacy and favorable safety, and, if positive, could significantly expand revenue opportunities in large, underserved markets driven by an aging population and rising chronic disease prevalence.

Want to see what kind of revenue ramp, margin shift, and valuation multiple are baked into that fair value? The narrative presents an earnings path built on ambitious growth, higher profitability, and a premium P/E assumption that most investors would usually associate with very different sectors.

Result: Fair Value of $22.19 (UNDERVALUED)

However, this hinges on successful trial outcomes and partner support. Setbacks in key programs or weaker collaboration revenue could quickly challenge that upbeat fair value story.

Another view: rich multiples against a cautious story

That $22.19 fair value narrative points to upside, but the current pricing tells a different story. At a P/S of 17.1x, Wave trades at more than 3x the US Pharmaceuticals average of 5.4x, close to 3x the peer average of 6x, and far above a fair ratio of 0.6x. For an unprofitable company with widening losses, that gap implies meaningful valuation risk if sentiment or revenue forecasts reset.

Before you lean too heavily on any single approach, it can be useful to see how the numbers stack up side by side in our valuation breakdown. This includes how the multiple compares across the sector and against the fair ratio, via See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With both upside potential and clear risks in focus, this is the kind of setup where you want to review the numbers yourself and decide quickly what you think. Start with the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If Wave Life Sciences is on your radar, do not stop there. Broaden your watchlist by lining up a few targeted stock ideas that fit your style.

• Target potential upside across quality companies that appear out of favour by scanning the 49 high quality undervalued stocks.
• Prioritize resilience and financial strength by checking stocks in the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for lesser known opportunities with strong fundamentals by reviewing the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.